NLRP3-IN-58 is a small molecule inhibitor specifically designed to target the NLRP3 inflammasome, a critical component of the innate immune system involved in the inflammatory response. This compound is characterized by its ability to modulate the activity of the NLRP3 protein, which plays a significant role in various inflammatory diseases. The inhibition of NLRP3 can potentially reduce the production of pro-inflammatory cytokines, making NLRP3-IN-58 a candidate for therapeutic applications in conditions such as autoimmune diseases, neurodegenerative disorders, and metabolic syndromes. The molecular structure of NLRP3-IN-58 includes specific functional groups that enhance its binding affinity and selectivity for the NLRP3 inflammasome. Additionally, its pharmacokinetic properties, such as solubility and bioavailability, are crucial for its effectiveness in vivo. Ongoing research continues to explore its efficacy and safety profile, aiming to establish its potential as a novel anti-inflammatory agent in clinical settings.

NLRP3-IN-58

2956014-05-2: NLRP3-IN-58 is a small molecule inhibitor specifically designed to target the NLRP3 inflammasome, a critical component of the innate immune system involved in the inflammatory response. This compound is characterized by its ability to modulate the activity of the NLRP3 protein, which plays a significant role in various inflammatory diseases. The inhibition of NLRP3 can potentially reduce the production of pro-inflammatory cytokines, making NLRP3-IN-58 a candidate for therapeutic applications in conditions such as autoimmune diseases, neurodegenerative disorders, and metabolic syndromes. The molecular structure of NLRP3-IN-58 includes specific functional groups that enhance its binding affinity and selectivity for the NLRP3 inflammasome. Additionally, its pharmacokinetic properties, such as solubility and bioavailability, are crucial for its effectiveness in vivo. Ongoing research continues to explore its efficacy and safety profile, aiming to establish its potential as a novel anti-inflammatory agent in clinical settings.

<p>NLRP3-IN-58 (Compound DS15) acts as an inhibitor of NLRP3 inflammasome activation, with an IC50 value of 3.85 μM, and is capable of inhibiting 33% of IL-1β release at a concentration of 10 μM.</p>

CAS 2956014-05-2

NLRP3-IN-58

NLRP3-IN-58

Ref: TM-T200969